Omeros

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Omeros and other ETFs, options, and stocks.

About OMER

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. 

CEO
Gregory A. Demopulos
CEOGregory A. Demopulos
Employees
202
Employees202
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
1994
Founded1994
Employees
202
Employees202

OMER Key Statistics

Market cap
1.09B
Market cap1.09B
Price-Earnings ratio
-7.61
Price-Earnings ratio-7.61
Dividend yield
Dividend yield
Average volume
4.15M
Average volume4.15M
High today
$17.65
High today$17.65
Low today
$9.03
Low today$9.03
Open price
$16.44
Open price$16.44
Volume
24.51M
Volume24.51M
52 Week high
$17.65
52 Week high$17.65
52 Week low
$2.95
52 Week low$2.95

Stock Snapshot

With a market cap of 1.09B, Omeros(OMER) trades at $15.25. The stock has a price-to-earnings ratio of -7.61.

During the trading session on 2025-12-25, Omeros(OMER) shares reached a daily high of $17.65 and a low of $9.03. At a current price of $15.25, the stock is +69.0% higher than the low and still -13.6% under the high.

Trading volume for Omeros(OMER) stock has reached 24.51M, versus its average volume of 4.15M.

Over the past 52 weeks, Omeros(OMER) stock has traded between a high of $17.65 and a low of $2.95.

Over the past 52 weeks, Omeros(OMER) stock has traded between a high of $17.65 and a low of $2.95.

OMER News

The Motley Fool 14h
Why Omeros Stock Skyrocketed Today

The company is on the brink of commercializing a unique medication. For the most part, the stock market tends to be sedate in the late holiday season. That sur...

Why Omeros Stock Skyrocketed Today
Benzinga 20h
Gold Edges Lower; Omeros Shares Jump

U.S. stocks traded higher midway through trading, with the Dow Jones index surging more than 200 points on Wednesday. the Dow traded up 0.48% to 48,673.55 whil...

Gold Edges Lower; Omeros Shares Jump
Benzinga 21h
FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ:OMER) Yartemlea (narsoplimab-wuug) for hematopoietic stem cell tran...

More OMER News

TipRanks 21h
D. Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains Buy rating

D. Boral Capital notes that Omeros (OMER) announced FDA approval of YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic micr...

Seeking Alpha 23h
Omeros wins FDA nod for transplant therapy

Omeros Corporation (OMER) announced on Wednesday that the U.S. FDA approved its lead asset, narsoplimab-wuug, as a treatment for hematopoietic stem cell transpl...

Omeros wins FDA nod for transplant therapy

People also own

Based on the portfolios of people who own OMER. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.